ribavirin [Copegus]
Sponsors
Hoffmann-La Roche
Conditions
Healthy VolunteerHepatitis C, Chronic
Phase 1
A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers
CompletedNCT01615393
Start: 2011-06-30End: 2011-10-31Updated: 2016-11-01
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
CompletedNCT01697436
Start: 2012-09-30End: 2012-12-31Updated: 2016-11-02
Phase 2
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4
CompletedNCT01057667
Start: 2010-02-28End: 2012-04-30Updated: 2016-11-02
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)
CompletedNCT01278134
Start: 2011-02-28End: 2012-10-31Updated: 2016-11-02
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment
WithdrawnNCT01579019
Start: 2012-07-31End: 2014-03-31Updated: 2016-11-02
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
CompletedNCT01628094
Start: 2012-06-30End: 2013-11-30Updated: 2016-11-02
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis
CompletedNCT01749150
Start: 2013-04-30End: 2015-02-28Updated: 2016-11-02
A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C
CompletedNCT01903954
Start: 2011-01-31End: 2013-05-31Updated: 2016-11-02
Phase 3
Phase 4
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
CompletedNCT00077649
Start: 2004-01-31End: 2005-12-31Updated: 2016-04-18
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
CompletedNCT00545233
Start: 2008-01-31End: 2010-12-31Updated: 2012-05-07
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
CompletedNCT01429792
Start: 2008-09-25End: 2013-06-10Updated: 2018-10-23
A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
CompletedNCT01447420
Start: 2011-02-28End: 2012-11-30Updated: 2016-07-25
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
CompletedNCT01585324
Start: 2012-01-31End: 2014-01-31Updated: 2015-07-24